Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
bioAffinity Technologies, Inc. ( (BIAF) ) has shared an announcement.
bioAffinity Technologies reported on April 1, 2026, that first-quarter 2026 unit sales of its CyPath® Lung diagnostic test rose 146% year over year based on preliminary unaudited data, surpassing internal projections and signaling stronger physician adoption and broader clinical use in lung cancer risk assessment. The company highlighted that CyPath® Lung targets a U.S. addressable market estimated at $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivors, with recent unit and revenue growth in 2024–2025 and ongoing clinical, commercial, and R&D initiatives positioning the test as a key tool in early lung cancer detection and long-term market expansion.
The most recent analyst rating on (BIAF) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held down primarily by weak financial performance (widening losses, revenue contraction, and rising cash burn despite improved leverage). Technicals are moderately supportive with positive momentum but appear overbought, while corporate updates are positive (studies, validation efforts, and clinician engagement) but remain early-stage relative to the current cash-flow profile.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection, particularly for lung disease. Its lead product, CyPath® Lung, is a laboratory developed test marketed through subsidiary Precision Pathology Laboratory Services for early-stage lung cancer detection using flow cytometry and AI analysis of sputum samples, and it is also advancing diagnostics for asthma and COPD.
Average Trading Volume: 8,473,987
Technical Sentiment Signal: Hold
Current Market Cap: $17.23M
For an in-depth examination of BIAF stock, go to TipRanks’ Overview page.